Login to Your Account



Little Impact to Ariad as Taltorvic Sinks Without a Ripple on CRL

By Catherine Shaffer
Staff Writer

Thursday, June 7, 2012
As anticipated, the FDA issued a complete response letter for Taltorvic (ridaforolimus) from Merck & Co. Inc. and Ariad Pharmaceuticals Inc. as a maintenance therapy for metastatic sarcoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription